Výsledky vyhledávání - "Garry Alan Weems"

Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

Autor: H. Jeffrey Wilkins, L. Carter, Judy S. Wang, Erika Hamilton, John Nemunaitis, Xiao Hu, Devalingam Mahalingam, John Sarantopoulos, Garry Alan Weems, Marshall Schreeder

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 25(12)

Purpose:Transcription factor retinoic acid receptor–related orphan receptor γ (RORγ) regulates type 17 effector T-cell differentiation and function and is key to immune cell regulation. Synthetic RORγ agonists modulate immune cell gene expressio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf0a78b01069052f7284b3ae03f41f10
https://pubmed.ncbi.nlm.nih.gov/30819679

Zobrazit plný text záznamu

Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based Therapy

Autor: Garry Alan Weems, Karen Kelly, Erzsébet Juhász, Jyoti D. Patel, Christopher G. Azzoli, Peter Y.Z. Jiang, Nicholas Iannotti, Petr Zatloukal, José Rodrigues Pereira, David Bodkin, Istvan Albert, Tony Koutsoukos

Publikováno v: Journal of Thoracic Oncology. 7:1041-1048

Introduction Pralatrexate, a folate analogue targeting dihydrofolate reductase, has antitumor activity in non–small-cell lung cancer (NSCLC). This randomized phase 2b trial was designed to further evaluate pralatrexate activity in NSCLC by estimati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8588e5c7aa858dafbe60a22f9d43cee7
https://doi.org/10.1097/jto.0b013e31824cc66c

Zobrazit plný text záznamu

Abstract CT132: Safety and dose selection for LYC-55716, a first-in-class RORγ agonist to treat solid tumors: Phase I results from an open-label, multicenter Phase I/IIa trial

Autor: Erika Hamilton, Judy S. Wang, Garry Alan Weems, Marshall Schreeder, H. Jeffrey Wilkins, Devalingam Mahalingam

Publikováno v: Cancer Research. 78:CT132-CT132

Background: LYC-55716, a first-in-class, oral, small-molecule agonist of the retinoic acid receptor-related orphan receptor γ (RORγ), is under development as a novel immuno-oncology agent for solid tumors. Preclinical data show that LYC-55716 modul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d318cd63aedd8a51d6eca3f11e8efebe
https://doi.org/10.1158/1538-7445.am2018-ct132

Zobrazit plný text záznamu

Abstract 5566: LYC-55716, a first-in-class RORγ agonist: Rationale and preclinical data to support clinical combinations with established immunotherapies

Autor: Xikui Liu, Laura L. Carter, Xiao Hu, Garry Alan Weems, H. Jeffrey Wilkins, Elizabeth Zawidzka, Yilin Gao, Hongxiu Li

Publikováno v: Cancer Research. 78:5566-5566

The retinoic acid-related orphan receptor γt (RORγt) is a nuclear receptor transcription factor that acts as an immune cell master control switch driving the generation and function of Th17 (helper) and Tc17 (cytotoxic) T cells. Preclinical data sh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9e92b6edcaf28a15d2d2bf2ae2b92ee5
https://doi.org/10.1158/1538-7445.am2018-5566

Zobrazit plný text záznamu

A phase 2A open-label, multicenter trial of the safety and efficacy of LYC-55716, a first-in-class oral, small-molecule RORγ agonist to treat select solid tumors

Autor: Karen Kelly, H. Jeffrey Wilkins, Christina Wu, Hope E. Uronis, L. Carter, Devalingam Mahalingam, Linda R. Duska, Stephen V. Liu, Melissa Lynne Johnson, Garry Alan Weems, Xiao Hu

Publikováno v: Journal of Clinical Oncology. 36:TPS2617-TPS2617

TPS2617Background: LYC-55716 is a first-in-class, oral, small-molecule agonist of the retinoic acid receptor–related orphan receptor γ (RORγ) under development as a novel immuno-oncology agent for ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f6370c6d96b6f45cd8eca740e70b1734
https://doi.org/10.1200/jco.2018.36.15_suppl.tps2617

Zobrazit plný text záznamu

A phase 1b trial of RORγ agonist LYC-55716 in combination with pembrolizumab to evaluate safety, efficacy, and immune biomarker profiles in patients with metastatic non-small cell lung cancer

Autor: Garry Alan Weems, H. Jeffrey Wilkins, Melissa Lynne Johnson, Shirish M. Gadgeel, D. Ross Camidge

Publikováno v: Journal of Clinical Oncology. 36:TPS9111-TPS9111

TPS9111Background: LYC-55716 is a first-in-class oral, small-molecule agonist of the retinoic acid receptor–related orphan receptor γ (RORγ) being developed as an immuno-oncology agent for solid tu...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::122711300bee92f3bef74a1223a464c6
https://doi.org/10.1200/jco.2018.36.15_suppl.tps9111

Zobrazit plný text záznamu

Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Tumor selection and evaluation of renal cell and bladder cancer for inclusion in phase 2a expansion

Autor: Laura L. Carter, Brian Fox, Xikui Liu, H. Jeffrey Wilkins, Xiao Hu, Hongxiu Li, Yilin Gao, Garry Alan Weems, Elizabeth Zawidzka

Publikováno v: Journal of Clinical Oncology. 36:424-424

424 Background: The master transcription factor retinoic acid receptor–related orphan receptor γt (RORγ) controls Type 17 effector T cell differentiation and function. Synthetic RORγ agonists modulate gene expression to enhance immune effector f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a4a1371b25a90844069445e6840d98ba
https://doi.org/10.1200/jco.2018.36.6_suppl.424

Zobrazit plný text záznamu

RORγ agonist LYC-55716, a novel small molecule immunotherapy: Rationale for clinical evaluation in non-small cell lung cancer based on translational and bioinformatic evaluation

Autor: Xikui Liu, Laura L. Carter, Xiao Hu, Hongxiu Li, Yilin Gao, H. Jeffrey Wilkins, Garry Alan Weems, Brian Fox, Elizabeth Zawidzka

Publikováno v: Journal of Clinical Oncology. 36:171-171

171 Background: Retinoic acid receptor–related orphan receptor γ (RORγ) agonists modulate immune cell gene expression to enhance effector function and decrease regulatory T cell formation and expression of checkpoint pathways. RORγ agonists have

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7e38c1265f7d59edb68f542ca8c2cac4
https://doi.org/10.1200/jco.2018.36.5_suppl.171

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání